Table 4. Summary of all related adverse events.

	NC-6004 dose level (in mg m−2)
	10	20	40	60	90	120	Total
n	1	1	3	3	6	3	17
Haematological toxicity
Blood and lymphatic system disorders
Thrombocytopenia	1	0	0	0	1	0	2
Non-haematological toxicity
Gastrointestinal disorder
Constipation	0	0	0	0	0	1	1
Dry mouth	0	0	0	1	0	0	1
Nausea	0	1	1	1	4	1	8
Paraesthesia oral	0	0	0	0	0	1	1
Tongue ulceration	0	0	0	0	1	0	1
Vomiting	0	0	1	1	4	1	7
General disorder and administration site conditions
Fatigue	1	1	0	1	4	2	9
Infusion site reaction	0	1	0	0	0	0	1
Malaise	0	0	0	0	0	1	1
Immune system disorders
Hypersensitivity	1	0	0	2	1	2	6
Metabolism and nutrition disorders
Anorexia	0	0	2	1	4	1	8
Decreased appetite	0	0	0	1	0	0	1
Dehydration	0	0	0	0	1	0	1
Hypomagnesemia	0	0	0	0	1	0	1
Nervous system disorder
Dizziness	0	0	0	0	0	1	1
Neuropathy peripheral	1	0	0	1	0	0	2
Peripheral sensory neuropathy	0	0	0	0	1	0	1
Renal and urinary disorder
Renal impairment	0	0	2	0	2	2	6
Skin and subcutaneous tissue disorder
Alopecia	0	0	0	0	0	1	1
Rash	0	0	0	0	0	1	1